We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04371185
Recruitment Status : Completed
First Posted : May 1, 2020
Last Update Posted : September 13, 2021
Information provided by (Responsible Party):
Bio-Thera Solutions

Brief Summary:
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2206 Injection vs Stelara® (EU-licensed and US-licensed) in healthy Chinese male subjects. A total of 270 healthy male subjects are planned to be included and randomized at a ratio of 1:1:1 to receive single 45mg/0.5ml BAT2206 Injection or Stelara® (EU-licensed and US-licensed).

Condition or disease Intervention/treatment Phase
Psoriasis Drug: BAT2206 Drug: Stelara(US-licensed) Drug: Stelara(EU-licensed) Phase 1

Detailed Description:

The study has a screening period of 14 days. PK blood samples will be collected from subjects to determine the serum concentration of Ustekinumab, thus to evaluate the similarity of the pharmacokinetics of the three study drugs.

The investigator will perform safety evaluation for vital signs, physical examinations, injection site reaction, ECG, clinical laboratory tests and adverse events throughout the study. Immunogenicity evaluation (ADA, ADA titration and nAb) will also be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blinded, Single-dose, 3-arms Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2206 Injection vs Ustekinumab Injection (Stelara) in Healthy Chinese Male Subjects
Actual Study Start Date : August 8, 2020
Actual Primary Completion Date : April 19, 2021
Actual Study Completion Date : April 19, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Ustekinumab

Arm Intervention/treatment
Experimental: BAT2206 injection
45mg; subcutaneous injection
Drug: BAT2206
45mg/0.5 ml; single dose;prefilled syringe; subcutaneous injection

Active Comparator: Stelara(US-licensed)
45mg; subcutaneous injection
Drug: Stelara(US-licensed)
45mg/0.5 ml; single dose;prefilled syringe; subcutaneous injection
Other Name: Ustekinumab

Active Comparator: Stelara(EU-licensed)
45mg; subcutaneous injection
Drug: Stelara(EU-licensed)
45mg/0.5 ml; single dose;prefilled syringe; subcutaneous injection
Other Name: Ustekinumab

Primary Outcome Measures :
  1. Pharmacokinetics Endpoint: Peak plasma concentration (Cmax) [ Time Frame: 0-4months ]
  2. Pharmacokinetics Endpoint: Area under the plasma concentration versus time curve (AUC0-inf) [ Time Frame: 0-4months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Chinese male healthy subjects aged from 18 to 55 years (including the boundary value);
  • BMI between 18-28kg/m2 (including boundary value) and body weight between 55-85kg;
  • Normal physical examination results or abnormal with no clinical significance according to the doctor's judgment;
  • The subject (including partner) has no pregnancy plan or sperm donation plan during the whole trial period and within 6 months after the completion of the study, and voluntarily adopts effective contraceptive measures;
  • Sign the informed consent before joining the study, and fully understand the content, process and possible risks;
  • Willing and able to comply with the visits and treatments of the trial protocol.

Exclusion Criteria:

  • Clinical laboratory examination results are abnormal and with clinical significance, or other clinical findings indicate diseases with clinical significance within one year prior to screening;
  • ECG is abnormal and has clinical significance (judged by the investigator);
  • With active infection within two months before screening, including acute and chronic infection and local infection;
  • Hepatitis B and/or Hepatitis C; or HIV antigen/antibody positive; or Treponema pallidum antibody positive;
  • Having taken any prescription drug, over-the-counter drug, any vitamin product or herbal medicine within 28 days before screening (or within 5 half-lives of the above drugs, whichever is longer);
  • Having participated in drug clinical trials within 3 months before the study administration, or planning to participate in other drug clinical trials during the study period;
  • Acute disease occurred or with concomitant medication from the screening to use of the study drug; major injury or surgery or fracture occurred within 4 weeks before enrollment, or surgery was planned during the study;
  • Having used ustekinumab, anti-tumor necrosis factor (TNF) or interleukin (IL) targeting agents, or having used any biological products or monoclonal antibodies within 3 months before screening;
  • Any immunoglobulin biologicals were used one year prior to screening;
  • Having received within 12 weeks prior to initiating treatment or planning to receive live virus or live vaccines during the study;
  • Suspected or confirmed as allergic constitution (allergic to variety of drugs or food), or allergic to ustekinumab, or severe allergic or allergic reaction to monoclonal antibody;
  • Blood donation or massive blood loss (> 450 ml) within 3 months before using the study drug, or planning to donate blood during the study, or having received blood transfusion within 8 weeks before screening;
  • Employees or relatives of all investigators, clinical centers, clinical research organizations or sponsors cannot be included in the group;
  • Subjects considered unsuitable by the investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04371185

Layout table for location information
The First Hospital of Jilin University
Jilin, China
Sponsors and Collaborators
Bio-Thera Solutions
Layout table for investigator information
Principal Investigator: Yanhua Ding the First Hospital of Jinlin University
Layout table for additonal information
Responsible Party: Bio-Thera Solutions
ClinicalTrials.gov Identifier: NCT04371185    
Other Study ID Numbers: BAT-2206-001-CR
First Posted: May 1, 2020    Key Record Dates
Last Update Posted: September 13, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Only one site study

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases
Dermatologic Agents